Abicipar Pegol Phase 3 AMD Studies

Related

• 

  Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S

  Allen Chiang, MD, FASRS

  Updates from the Field

  2019

• 

  12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial

  Rishi P. Singh, MD

  Updates from the Field

  2022

• 

  Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

  Jared S. Nielsen, MD, MBA

  Updates from the Field

  2022